Arsenic trioxide as a therapeutic agent for ALK-driven cancers
Grant Data
Project Title
Arsenic trioxide as a therapeutic agent for ALK-driven cancers
Principal Investigator
Professor Tse, Eric Wai Choi
(Principal Investigator (PI))
Duration
30
Start Date
2021-10-01
Amount
1125732
Conference Title
Arsenic trioxide as a therapeutic agent for ALK-driven cancers
Presentation Title
Keywords
ALK-driven cancers, anaplastic lymphoma kinase, arsenic trioxide, drug resistance, tyrosine kinase inhibitor
Discipline
Cancer,Others - Medicine, Dentistry and Health
Panel
Biology and Medicine (M)
HKU Project Code
17114621
Grant Type
General Research Fund (GRF)
Funding Year
2021
Status
On-going
Objectives
1 To examine if ALK oncogenic fusion and gain-of-function mutants are targets of arsenic trioxide in ALK-driven non-small cell lung cancer (NSCLC), diffuse large B-cell lymphoma (DLBCL) and neuroblastoma (NB). 2 To examine the mechanisms of arsenic trioxide-induced degradation of these ALK fusion proteins and ALK gain-of-function mutants in respective cancer models. 3 To examine the effects of arsenic trioxide in NSCLC with TKI-resistant EML4-ALK mutants. 4 To examine the effects of arsenic trioxide in xenograft murine models of these ALK-driven cancers